Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Oh...It didn't start trading?

<< Previous

Bullboard Posts

Next >>

Comment by losingmyshirton Nov 17, 2020 4:42pm

162 Views

Post# 31918852

RE:RE:RE:Oh...It didn't start trading?

Scotty wrote: Correct me if I'm wrong but doesn't KLY need 6 months worth of operating capital to get relisted? If so, where is it coming from? The last PP? I might have missed that info.

Yes Scotty that 6 months of funding could be a major problem. I recall that there was something like that.
It blows my mind that we have been left hanging for 6 months.
Basically we are Fooked, well we were Fooked a long time ago.

Maybe better DD was needed before investing anything in this shythole of an investment..Live and learn..

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages